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Proteolytic enzymes are involved in cancer invasion and meta-
stasis by their capability to degrade basement membranes and
extracellular matrix proteins surrounding normal tissue (Liotta et
al, 1982; Dan¿ et al, 1985; Mignatti and Rifkin, 1993; Andreasen
et al, 1997). One of the key enzymes is urokinase-type plas-
minogen activator (uPA) that, in its active form, catalyses the
conversion of plasminogen into plasmin, which has the ability to
degrade several components of the extracellular matrix and to
activate some prometalloproteases (Dan¿ et al, 1985; Duffy, 1992;
Mignatti and Rifkin, 1993; Andreasen et al, 1997). Binding of
uPA to its receptor (uPAR) strongly enhances uPA-mediated
plasminogen activation and localizes the proteolytic activities on
the cell surface (Dan¿ et al, 1994). The proteolytic activity of uPA
is controlled by two members of the serpin family of protease
inhibitors, i.e. plasminogen activator inhibitor type-1 (PAI-1) and
type-2 (PAI-2) (Andreasen et al, 1990). By forming complexes
with uPA bound to uPAR, PAI-1 promotes the clearance of proteo-
lytic activities from the cell surfaces and recycling of unbound
uPAR back to the cell surface, thereby regulating the overall
invasive and metastatic behaviour of cancer cells (Andreasen et al,
1997; Chapman et al, 1997).
Several investigations have demonstrated the prognostic value of
uPA and PAI-1 in breast cancer patients, and high levels of
both components have been shown to be independent and strong
prognostic parameters predicting disease recurrence and overall
survival (reviewed in Duffy, 1996; Schmitt et al, 1997). Mostly,
ELISA methods have been used for determination of both uPA and
PAI-1, either in detergent-treated tumour tissue extracts (J￿nicke
et al, 1989, 1990, 1991, 1993, 1994a) or in cytosolic extracts
routinely prepared for the assessment of steroid hormone receptors
[oestrogen receptor (ER) and progesterone receptor (PgR)] (Duffy
et al, 1990; Foekens et al, 1992; Spyratos et al, 1992; Gr¿ndahl-
Hansen et al, 1993; Foekens et al, 1994; J￿nicke et al, 1994a; Fern￿
et al, 1996). Recently, two new ELISAs were developed which
proved to be suitable for the determination of uPA and PAI-1 in
breast tumour tissue (Grebenschikov et al, 1997). These in-house
ELISAs are based on a combination of polyclonal antibodies used in
a sandwich assay format to which special features are attributed
because uPA and PAI-1, and eventually complexes between both
components, can be simultaneously assessed in one and the same
ELISA frame. In the present study, the in-house ELISAs were
applied to the determination of uPA and PAI-1 in breast tumour
cytosols and in corresponding detergent extracts of pellets obtained
after ultracentrifugation carried out when preparing the cytosolic
fractions derived from 892 primary breast cancer patients. The prog-
nostic impact of the uPA and PAI-1 antigen levels in cytosols and
pellet extracts was subsequently evaluated to assess the established
clinical significance of the two components. Furthermore, the levels
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of uPA and PAI-1 were correlated to those obtained earlier with
ELISAs based on commercial reagents.
MATERIALS AND METHODS
Patients and tumour characteristics
In the present study, 892 patients with primary operable breast
cancer (modified mastectomy, 446 patients; breast-conserving
lumpectomy, 446 patients) were included. Inclusion criteria for
patients from whom tumour biopsies or cytosol samples were
stored in the tumour bank of the Rotterdam Cancer Centre (Dr
Daniel den Hoed Kliniek) were: (i) primary diagnosis of breast
cancer between 1979 and 1989; (ii) no signs of distant metastasis
at diagnosis; (iii) no previous diagnosis of carcinoma, with the
exception of basal cell skin cancer and cervical cancer stage Ia;
(iv) no evidence of disease within 1 month after primary surgery.
In cases of mastectomy after an initial lumpectomy for residual
disease, the mastectomy is considered as (part of) primary treat-
ment. The median number of lymph nodes removed surgically was
11. Patients without primary surgery or patients who received
neoadjuvant treatment before primary surgery were excluded.
Median age of the patients at the time of surgery was 56 years
(range 25—89 years). Radiotherapy was given to 82% of the
patients: on the breast/thoracic wall to 617 patients and/or on the
axilla to 262 patients, and/or on one or more lymph node areas
other than the axilla to 297 patients. Although two of the 446
node-negative patients received adjuvant chemotherapy, none of
them received adjuvant hormonal therapy. Of the 437 node-posi-
tive patients (for nine patients, nodal status was missing), adjuvant
chemotherapy (mainly CMF; cyclophosphamide, methotrexate,
5-fluorouracil) was given to 146 patients, whereas 59 patients
received hormonal therapy either alone (45 patients) or in combi-
nation with chemotherapy (14 patients). All patients were
routinely examined every 3—6 months during the first 5 years of
follow-up and once a year thereafter. During follow-up, 367
patients (41%) showed relapse and were counted as failures in the
analysis for relapse-free survival. Fifty-seven patients (6%) died
without evidence of disease and were censored at last follow-up in
Table 1 Relationships between uPA and PAI-1 levels in 892 cytosols and pellet extracts with patient and tumour characteristics
Number of Percentage of tumours above the median valueb
Characteristics
patientsa
uPAcyt.
c uPApel.
c PAI-1cyt.
c PAI-1pel.
c
All patients 892 50 50 50 50
Age at surgery (years)
≤40 122 53 50 55 52
41–55 308 49 47 46 43
56–70 295 53 55 51 58
> 70 167 46 47 53 48
P-valued 0.12 0.97 0.32 0.24
Menopausal status
Premenopausal 368 51 47 47 44
Post-menopausal 524 50 53 52 54
P-valuee 0.32 0.51 0.07 0.005
Tumour size
T1 (≤ 2 cm) 407 48 57 46 48
T2 (> 2–5 cm) 399 52 45 52 52
T3/4 (> 5 cm) 86 51 42 57 46
P-valuef 0.32 <0.001 0.03 0.74
Nodal status
N0 446 48 52 47 51
N1–3 216 53 53 52 50
N>3 221 52 44 55 48
P-valuef 0.44 0.05 0.30 0.55
Grade
Well/moderate 152 51 50 41 46
Poor 510 51 51 54 53
P-valuee 0.60 0.83 0.006 0.04
ER positiveg
No 209 65 57 64 57
Yes 682 46 48 46 48
P-valued 0.001 0.003 0.08 <0.001
PgR positiveg
No 249 61 55 63 61
Yes 628 46 48 45 45
P-valued 0.08 0.33 <0.001 <0.001
aOwing to missing values the numbers do not always add up to 892. bThe median values in ng mg–1 protein were 0.73 for uPAcyt., 7.26 for uPApel., 1.62 for
PAI-1cyt. and 5.29 for PAI-1pel.
cuPAcyt., uPApel., PAI-1cyt. and PAI-1pel. denote uPA and PAI-1 levels determined with the in-house assays in cytosol (cyt.) and pellet
extracts (pel.) respectively. dP-value for Spearman rank correlation. eP-value for Wilcoxon rank sum test (for grade: well and moderate combined). fP-value for
Kruskal–Wallis test, including a Wilcoxon-type test for trend. gCut-off point used for ER and PgR, 10 fmol mg–1 protein.1192 JH de Witte et al
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the analysis for relapse-free survival. Two hundred and twenty-
eight patients (26%) died after a previous relapse. A total of 285
(63 + 222) patients (32%) were counted as failures in the analysis
for overall survival. The median follow-up period of patients alive
was 99 months (range 12—167 months). Further characteristics of
patients and tumours are listed in Table 1.
Tumour tissue extraction
Tumour tissues were stored in liquid nitrogen and pulverized in the
frozen state with a microdismembrator as recommended by the
European Organization for Research and Treatment of Cancer
(EORTC, 1980) for processing of breast tumour tissue for cytosolic
determination of steroid hormone receptors (ER and PgR) (EORTC
Breast Cancer Cooperative Group). The resulting tissue powder was
homogenized in EORTC receptor buffer [10 mM dipotassium
hydrogen phosphate, containing 1.5 mM dipotassium chloride
EDTA, 3 mM sodium azide, 10 mM monothioglycerol and 10% (v/v)
glycerol, pH 7.4]. The homogenate was centrifuged for 30 min at
100 000 g and 4°C to obtain the supernatant fraction (cytosol). The
100 000 g pellets were rehomogenized with an Ultraturrax tissue
homogenizer in 20 mM Tris-HCl (pH 8.5) containing 125 mM
sodium chloride. After the addition of Triton X-100 to a final
concentration of 1% and subsequent incubation for 16—20 h at 4°C,
the supernatant fractions obtained by centrifugation at 30 000 g at
4°C were designated as pellet extracts.
Steroid hormone receptor assays
ER and PgR levels were determined by ligand binding assay or
enzyme immunoassay in cytosols as described earlier (Foekens et
al, 1989). The cut-off level used to classify tumours as ER or PgR
positive and negative was 10 fmol mg—1 cytosolic protein.
ELISAs for uPA and PAI-1
The antigen levels of uPA and PAI-1 were assessed with ELISAs.
For determination of their levels in cytosols, two different assay
formats were used, i.e. the previously evaluated ELISAs (Foekens
et al, 1992, 1994), using reagents from kits which are now
commercially available (American Diagnostica, Greenwich, CT,
USA) and the newly established uPA and PAI-1 ELISAs based on
polyclonal antibodies (Grebenschikov et al, 1997). The latter ￿in-
house￿ ELISAs were also used for the determination of uPA and
PAI-1 levels in the corresponding pellet extracts. The respective
antigen levels are referred to as uPAin-house assay, PAI-1in-house assay,
uPAAD and PAI-1AD in the tables and figures. Triton X-100 did not
have any influence on the ELISAs up to a concentration of 1%. An
aliquot of a pooled breast tumour cytosol sample was analysed in
each assay run to assess the between-assay variation, which was
found to be below 15% for all assays used. The within-assay vari-
ation of samples measured in duplicate were all below 5%.
Protein determinations
The Bradford method for protein analysis (Bradford, 1976) was
used with the Bio-Rad reagent with human serum albumin (HSA)
(KabiVitrum, Stockholm, Sweden) as a standard in order to
express antigen levels per mg of total protein. Triton X-100 up to a
concentration of 1% did not interfere with the protein determina-
tion in pellet extracts.
Statistical analysis
The strength of the associations of uPA and PAI-1 levels deter-
mined in cytosols and pellet extracts with each other, age and
steroid hormone receptor status was tested by Spearman rank
correlation (rs). The associations of uPA and PAI-1 with other
clinical variables were tested with the non-parametric Wilcoxon
rank-sum test or the Kruskal—Wallis test, including a Wilcoxon-
type test for trends across ordered groups when appropriate.
Relapse-free and overall survival probabilities were calculated by
the actuarial method of Kaplan and Meier (1958). The log-rank
test for trend was used to test ordered variables. Both uni- and
multivariate analyses, including tests for interactions, were
performed using the Cox proportional hazard model, and the asso-
ciated likelihood ratio test was used to test for differences. To
include the largest possible number of patients in multivariate
analyses, patients with missing values for ER or PgR (n = 16) and
missing information on nodal status (n = 9) were included as sepa-
rate groups (not shown in the tables). All computations were
carried out with the Stata statistical package, release 5.0 (Stata,
College Station, TX, USA). Two-sided P-values below 0.05 were
considered to be statistically significant.
Table 2 Levels of uPA and PAI-1 in cytosols and pellet extracts
Sample First quartile Median Third quartile Range Mean ± s.d.
Cytosols
uPAAD 0.20 0.60 1.25 0.00–7.73 0.91 ± 0.98
PAI-1AD 8.97 15.43 25.48 0.02–479.38 22.23 ± 29.79
uPAin-house assay 0.38 0.73 1.24 0.02–12.66 0.95 ± 0.95
PAI-1in-house assay 1.06 1.62 2.62 0.14–48.62 2.43 ± 3.37
Pellet extracts
uPAin-house assay 4.14 7.26 12.53 0.00–315.40 11.3–21.83
PAI-1in-house assay 3.29 5.29 8.64 0.26–300.60 9.3 ± 18.11
The antigen levels of uPA and PAI-1 were determined in cytosols and pellet extracts with the ELISAs using commercial reagents (uPAAD and
PAI-1AD) and the in-house-developed ELISAs (uPAin-house assay and PAI-1in-house assay). The antigen levels are expressed as ng mg–1 total protein.uPA and PAI-1 prognosis in cytosols and pellet extracts 1193
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RESULTS
uPA and PAI-1 antigen determinations in cytosols and
pellet extracts
The antigen levels of uPA and PAI-1 in 892 cytosols were deter-
mined with two different ELISA methods using commercial
reagents and in-house-developed assays (Table 2). The mean and
median levels of uPA as determined by both ELISAs were similar.
However, the mean and median PAI-1 levels assessed by the two
ELISAs differed by a factor of 10, the in-house ELISA measuring
values ten times lower than the ELISA with commercial reagents.
The overall association between the two ELISA methods is
demonstrated by the highly significant correlations between the
cytosolic levels of uPA (rs = 0.85, P < 0.0001) and of PAI-1
(rs = 0.90, P < 0.0001) (Figure 1A and B). When compared with
the cytosolic levels of uPA and PAI-1 assessed with the in-house
ELISAs, the mean and median levels determined in the pellet
extracts were substantially higher, differing from one another by a
factor of 10 (uPA) and a factor of 4 (PAI-1) respectively (Table 2).
Clear and statistically significant correlations were found between
the antigen levels in cytosols and corresponding pellet extracts
(rs = 0.60, P < 0.0001 for uPA and rs = 0.65, P < 0.0001 for PAI-1)
(Figure 1C and D). In addition, the levels of uPA and PAI-1 deter-
mined with the in-house assays significantly correlated with each
other (rs = 0.66, P < 0.0001 for cytosols and rs = 0.58, P < 0.0001
for pellet extracts).
Relation of uPA and PAI-1 levels to patient and tumour
characteristics
The associations of cytosolic uPA and PAI-1 levels analysed with
the commercial reagents with patient and tumour characteristics
have been documented previously (Foekens et al, 1992, 1994).
Therefore, in the present study, merely the levels of uPA and
PAI-1 determined in cytosols and pellet extracts with the newly
established in-house assays were related to patient and tumour
characteristics (Table 1). The levels of uPA or PAI-1, when
measured in cytosols, were not significantly related to age,
menopausal status or nodal status. In contrast to the levels of uPA
in cytosols, those of PAI-1 were higher in larger tumours. Similar
results were obtained for the pellet extracts, with the exception of
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Figure 1 Comparison of results obtained with different ELISAs for uPA and PAI-1. Antigen levels of uPA and PAI-1 in 892 cytosols were determined with two
different ELISA methods using commercial (American Diagnostica, AD) reagents and in-house-developed assays. The scatter plots present the overall
correlation between the results obtained with the ELISAs for uPA (A) and PAI-1 (B). The solid lines correspond to the lines of equality. Likewise, the antigen
levels assessed in cytosols and pellet extracts with the in-house ELISA for uPA (C) and PAI-1 (D) were correlated with one another. Values below the assay
sensitivity were set at half the value of the detection limits of each ELISA. The antigen levels were all expressed as ng mg–1 of total protein measured in the
cytosols and pellet extracts1194 JH de Witte et al
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Table 3 Cox univariate and multivariate analysis of relapse-free and overall survival
Factor Relapse-free survival Overall survival
Univariate Multivariate Relative Univariate Multivariate Relative
P-value P-value relapse ratea P-value P-value death ratea
Age and menopausal status <0.001b <0.001b <0.001b <0.001b
Age/premenopausalc 0.63 (0.49–0.81) 0.83 (0.59–1.17)
Age/postmenopausalc 1.01 (0.86–1.18) 1.38 (1.17–1.63)
Post- vs. premenopausald 1.40 (0.90–2.17) 1.18 (0.68–2.06)
Tumour size <0.001 0.06 <0.001 0.002
2–5 cm vs. ≤ 2 cm 1.21 (0.95–1.54) 1.24 (0.93–1.64)
> 5 cm vs. ≤ 2 cm 1.56 (1.07–2.27) 2.02 (1.38–2.98)
Nodal status <0.001 <0.001 <0.001 <0.001
N1–3 vs. N0 1.53 (1.11–2.10) 2.11 (1.49–2.98)
N>3 vs. N0 2.99 (2.22–4.03) 3.59 (2.58–4.99)
Adjuvant therapy (yes vs. no) 0.06e 0.01 0.68 (0.50–0.92) <0.001e 0.02 0.68 (0.49–0.95)
ER/PgRf 0.001 0.05 <0.001 <0.001
Pos/neg vs. neg/neg 0.64 (0.42–0.95) 0.54 (0.35–0.82)
Neg/pos vs. neg/neg 0.77 (0.49–1.22) 0.52 (0.31–0.87)
Pos/pos vs. neg/neg 0.70 (0.53–0.91) 0.45 (0.33–0.59)
aRelative hazard rate (95% confidence interval) of multivariate analysis. bAge and menopausal status combined. cAge in decades tested separately for pre- and
post-menopausal patients. dPost-menopausal compared with premenopausal. eIn node-positive patients. fCut-off points used for ER and PgR, 10 fmol mg–1
protein.
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Figure 2 Actuarial relapse-free and overall survival curves for all 892 breast cancer patients stratified by the levels of uPA (A) and (C) and PAI-1 (B) and (D)
determined in cytosolic extracts of tumour tissue. Patients were divided into groups according to the quartiles (Q1–Q4) of the respective levels, as listed in Table
2. Shown are the P-values from the log-rank test for trend. RHR (95% CI), relative hazard rate (95% confidence interval) calculated by Cox multivariate
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the observed negative association of uPA with tumour size and
with nodal status and the higher PAI-1 levels in tumours from
post-menopausal patients. Neither cytosolic uPA levels nor those
measured in pellet extracts were associated with tumour grade. In
contrast, the levels of PAI-1 were significantly higher in poorly
differentiated tumours. In general, lower levels of uPA and
PAI-1 were measured in steroid hormone receptor-positive
tumours. However, these negative correlations were very weak
and the strongest Spearman correlation coefficient observed was
rs = —0.15.
Relation of uPA and PAI-1 levels to (relapse-free)
survival
In univariate and multivariate Cox regression analyses, classical
prognostic variables including age and menopausal status, tumour
size, nodal status and steroid hormone receptor status were all
significantly associated with the length of relapse-free survival
(RFS) and overall survival (OS) (Table 3). Moreover, adjuvant
treatment was associated with a favourable prognosis. In
univariate analyses, poor differentiation grade of the tumour was
associated with an early relapse (P < 0.001) and death (P = 0.01).
Grade was not included in the basic multivariate model for RFS
and OS shown in Table 3 because of too many missing values. To
study their possible relationships with RFS and OS, the levels of
uPA and PAI-1 measured with the in-house ELISAs were divided
into four groups (Q1—Q4) by their respective quartiles, as shown in
Table 2. There was a trend towards a worse RFS and OS with
increasing cytosolic levels of uPA and PAI-1, the best prognosis
being observed in patients with tumours containing uPA or PAI-1
levels in the first quarter (Q1) and the worst prognosis being
observed in patients with tumours containing uPA and PAI-1 levels
in the fourth quarter (Q4) (Figure 2). Similar relationships with
poor RFS and OS, although less pronounced, were seen for uPA
and PAI-1 levels measured in the pellet extracts (data not shown).
In Cox multivariate regression analyses corrected for age,
menopausal status, tumour size, lymph node status, steroid
hormone receptor status and adjuvant therapy (basic multivariate
model depicted in Table 3), cytosolic uPA and PAI-1 levels were
significantly related to a poor RFS and OS, either when added
as a categorical or as a log-transformed continuous variable.
Comparable, although weaker, relationships with a poor RFS and
OS were found for uPA and PAI-1 measured in the pellet extracts
(Table 4). Regarding the prognostic value of uPA and PAI-1 as
assessed with the commercial reagents, the levels of both compo-
nents in cytosols, also divided into quarters, added significantly to
the model, with relative rates of relapse and of death comparable
to those found for the in-house assays (Table 4).
Table 4 Cox multivariate analysis of relapse-free and overall survival
Factor Relapse-free survival Overall survival
Relative relapse ratea P-valueb Relative relapse ratea P-valueb
Cytosolsc
uPAin-house assay 0.02 <0.001
Q2 vs. Q1 1.22 (0.89–1.67) 1.39 (0.95–2.05)
Q3 vs. Q1 1.32 (0.97–1.79) 1.80 (1.24–2.60)
Q4 vs. Q1 1.61 (1.19–2.18) 2.18 (1.51–3.13)
PAI-1in-house assay <0.001 <0.001
Q2 vs. Q1 1.21 (0.88–1.67) 1.28 (0.87–1.88)
Q3 vs. Q1 1.47 (1.08–1.98) 1.59 (1.11–2.27)
Q4 vs. Q1 1.88 (1.39–2.53) 2.31 (1.63–3.26)
uPAAD 0.002 <0.001
Q2 vs. Q1 1.52 (1.12–2.07) 1.88 (1.30–2.71)
Q3 vs. Q1 1.23 (0.90–1.68) 1.67 (1.15–2.42)
Q4 vs. Q1 1.73 (1.27–2.34) 2.35 (1.63–3.39)
PAI-1AD <0.001 <0.001
Q2 vs. Q1 1.14 (0.83–1.57) 1.21 (0.83–1.78)
Q3 vs. Q1 1.56 (1.14–2.11) 1.63 (1.13–2.34)
Q4 vs. Q1 1.84 (1.36–2.49) 2.41 (1.70–3.42)
Pellet extractsc
uPAin-house assay 0.06 <0.001
Q2 vs. Q1 1.03 (0.77–1.39) 1.40 (0.98–2.01)
Q3 vs. Q1 1.05 (0.77–1.42) 1.72 (1.19–2.47)
Q4 vs. Q1 1.43 (1.07–1.91) 2.08 (1.46–2.95)
PAI-1in-house assay 0.003 <0.001
Q2 vs. Q1 1.10 (0.80–1.51) 1.12 (0.77–1.63)
Q3 vs. Q1 1.44 (1.06–1.95) 1.61 (1.14–2.28)
Q4 vs. Q1 1.67 (1.24–2.27) 2.11 (1.50–2.97)
aRelative hazard rate (95% confidence interval) of multivariate analysis corrected for the basic model given in Table
3, including age/menopausal status, tumour size, nodal status, ER/PgR status and adjuvant therapy. Factors were
added separately to the basic model. bP-values for the associated likelihood ratio test for the quarters. cQ1, first
quarter; Q2, second quarter; Q3, third quarter; Q4, fourth quarter. The quartiles of the antigen levels determined with
the in-house assays (uPAin-house assay and PAI-1in-house assay) and the commercial reagents (uPAAD and PAI-1AD) are listed
in Table 2.1196 JH de Witte et al
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There were no statistically significant interactions of uPA or
PAI-1 with each other or with any of the classical prognostic
parameters in the analyses for RFS and OS. Therefore, there are no
reasons to assume that the prognostic value of uPA and/or PAI-1 is
different in subgroups of patients. To visualize the combined prog-
nostic value of uPA and PAI-1 with respect to the application of
adjuvant therapy in the clinically important subgroup of node-
negative patients, both factors were divided by their median value.
The resulting actuarial RFS and OS curves as a function of
combined uPA and PAI-1 status as determined by the in-house
ELISAs are shown in Figure 3.
DISCUSSION
In the present study, we evaluated the clinical relevance of uPA
and PAI-1 antigen levels as measured in 892 breast tumour
cytosols and the corresponding 100 000 g pellets re-extracted with
detergent (Triton X-100)-containing buffer using newly developed
ELISAs for the respective components. In this relatively large
series of patients, the prognostic value of uPA and PAI-1 in breast
carcinomas documented in previous prospective and retrospective
studies as reviewed by Duffy (1996) and Schmitt et al (1997) has
been confirmed. With respect to the analysis of cytosols, high
levels of uPA and PAI-1 were associated with a significantly
shorter RFS and OS. Moreover, in multivariate analyses which
included classical prognostic parameters, cytosolic levels of both
uPA and PAI-1 appeared to be important independent predictors of
early relapse and death. The prognostic significance was ascer-
tained by comparing RFS and OS for patients divided into quarters
of the corresponding uPA and PAI-1 antigen levels, and by
analysing RFS and OS as a function of uPA and PAI-1 analysed as
continuous variables. The evaluation of survival by means of the
quarters of antigen levels to discriminate between low-risk and
high-risk patients represents a more unprejudiced approach
compared with determination of optimized cut-off points which
results in overfitting.
Interestingly, the 100 000 g pellets, which may be considered as
incidental products of ultracentrifugation when preparing the
cytosolic fractions, also provide prognostic information. However,
when using the same assay, the pellet extracts contained substan-
tially higher concentrations of uPA and PAI-1 (Table 2), but
provided less prognostic information than the cytosolic extracts
(Table 4). These findings seem to be in apparent contrast to those
obtained by J￿nicke et al (1994a), who demonstrated that determi-
nation of uPA, but not PAI-1, in detergent extracts of breast tumour
tissue yields improved prognostic information (expressed as rela-
tive risk to relapse) compared with uPA in cytosol fractions. In the
last investigation, the detergent was applied directly to tumour
homogenates, whereas in the present study pellets which remained
after preparation of the cytosols were treated with detergent.
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Although the detergent-treated homogenates, as used by J￿nicke
et al (1994a), would contain uPA released from membranous
components (uPAR) besides cytosolic uPA, our pellet extracts
should contain exclusively the membrane-associated form of uPA.
The possible additional prognostic value of uPA/uPAR complexes
remains to be proven, for which purpose a recently developed
ELISA for measurement of these complexes (De Witte et al, 1997)
can be used.
In the clinical studies referred to above, various ELISAs have
been used for the quantitative determination of uPA and PAI-1 in
extracts of breast tumour biopsies. These ELISAs, whether applied
as commercial kits or as in-house immunoassays, are all based on
different combinations of monoclonal and/or polyclonal antibodies
which are specifically directed against the component to be
assessed in the biological sample. The newly developed in-house
ELISAs for uPA and PAI-1 consist of specific polyclonal anti-
bodies for catching and detection of analyte (Grebenschikov et al,
1997). In contrast, in the uPA and PAI-1 ELISA format composed
of commercial reagents, a combination of monoclonal and poly-
clonal antibodies (PAI-1 ELISA) or only monoclonal antibodies
(uPA ELISA) were used. The use of different antibodies with
different specificities and affinities, as well as the heterogeneity of
uPA in tumour samples, most probably underlies the disperse distri-
bution of data when examining the overall association between the
ELISA methods for uPA (Figure 1A). Indeed, uPA can be present
in several different forms in tumour tissue extracts, including
single-chain pro-uPA, two-chain uPA, amino-terminal fragment
(ATF) of uPA, complexes of (pro-) uPA with uPAR, PAI-1 and/or
PAI-2, and different ELISA formats may recognize each of the
various forms of uPA with different efficiencies. Moreover, the
combined commercial reagents in the ELISA format for
uPA do not detect LMW-uPA (Grebenschikov et al, 1997).
Notwithstanding the variation between the values obtained by the
two uPA ELISAs, the mean and median levels of uPA determined
by both methods were highly comparable to each other. The scatter
plot for the overall association between the PAI-1 data reveals a
very limited spread of data, despite a systematic bias relative to the
line of equality over the whole range of PAI-1 concentrations
(Figure 1B). This difference (approximately a factor of 10) between
PAI-1 antigen levels obtained by both ELISAs may be explained,
for the largest part, by a difference in calibration of the PAI-1 stan-
dards used in the two ELISAs. In fact, both PAI-1 ELISAs used
standards with different immunoreactive potencies, as reflected by
the divergent ELISA responses obtained when both standards were
assayed in the in-house ELISA for PAI-1 (Grebenschikov et al,
1997). Moreover, when using the commercial PAI-1 standard in the
two assay formats, the PAI-1 antigen values measured in cytosols
by both ELISA methods were almost equal to one another, as
reported earlier (Grebenschikov et al, 1997). Furthermore, the
narrow dispersion of data is indicative of assessment of PAI-1,
which is considered to be present in just a few different forms, with
comparable efficiencies in both ELISA methods.
A direct comparison of both uPA and PAI-1 levels measured in
breast tumour extracts, including cytosols, with those reported in
the literature is quite difficult given the lack of standardization
(Benraad et al, 1996) because different antibodies and standards as
well as different extraction buffers were used in the various
studies. The application of different ELISA methods, each using
different antibodies with different specificities towards the various
components, may disclose which of the molecular forms of uPA
and/or PAI-1 present in tumour tissue extracts is responsible for
the observed relationship with prognosis. To specifically address
this aspect, an alternative study design is desired in which identical
aliquots of the patient samples are simultaneously analysed by the
different assays. The strong statistically significant correlations
between the cytosolic levels of either uPA or PAI-1, as determined
by the different ELISA formats in this investigation, suggest,
however, that both methods exert comparable prognostic informa-
tion, and that either assay can be used to assess the uPA and PAI-1
status of the breast tumour.
The corroboration of the prediction of prognosis on the basis of
uPA and PAI-1, assessed by the independent ELISA methods for
each of the components, once again emphasizes the established
prognostic role and usefulness of these parameters in selection of
primary breast cancer patients at high or low risk of recurrence.
This also applies to the patients with node-negative disease, who
as a group have a relatively favourable prognosis. Simultaneous
measurement of uPA and PAI-1 might be helpful in identifying
those node-negative patients who will experience a recurrence and
might benefit from adjuvant therapy. Within this framework, the
results of an ongoing German multicentre clinical study on adju-
vant chemotherapy in node-negative breast cancer, based on selec-
tion by the tumour levels of uPA and PAI-1 (J￿nicke et al, 1994b),
are of special interest.
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